Clinical Trial

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Study acronym: Mintaka
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
Protocol Amendment History 5 changes
notable Trial sites expanded: 91 -> 103 locations 2026-07-21
notable Trial sites expanded: 73 -> 91 locations 2026-06-24
notable Trial sites expanded: 47 -> 73 locations 2026-05-23
notable Trial sites expanded: 30 -> 47 locations 2026-04-24
notable Trial sites expanded: 16 -> 30 locations 2026-03-31
Trial Details
NCT Number NCT07282574
Lead Sponsor Hoffmann-La Roche
Conditions Progressive Multiple Sclerosis
Enrollment 360 participants
Start Date 2026-03-10
Primary Completion 2028-05-30 (estimated)
Study Completion 2030-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20